DAC linker is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-29. Numbers and descriptions here follow the published literature rather than marketing material.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
On the second issue, CAS stated they could not "permit an athlete to establish how a substance came to be present in his body by little more a denial that he took it", that there was "nothing more than speculation, unsupported by any evidence of any kind", that Elsalam did not substantiate her hypothesis with any evidence aside from the receipt presented, that little attempt was made "to establish the causal link" and that it was "noteworthy" that Elsalam had not "produced a single piece of evidence demonstrating or even substantiating that other consumers (including athletes) having purchased and eating [sic] meat in Egypt within the relevant time have been subjected to food contamination with [ractopamine]" CAS upheld WADA's appeal, ruling a violation was committed, and that Elsalam had not met her burden of proof, so the violation "must be deemed to have been intentional". It was explicitly stated that they had "not pronounced the Athlete as a 'cheater'". Elsalam's ineligibility period was extended to four years. In October 2017 at a WADA conference, it was suggested in relation with ractopamine:
The US Central Intelligence Agency (CIA) launched a video and a Telegram channel calling on Russians dissatisfied with the situation in Ukraine as well as the domestic situation to share intelligence with the agency and provided instructions on how to do so.
T4-translation seeks to (1) advance scientific knowledge to paradigms of disease prevention, and (2) move health practices established in T3 into population health impact. Finally, T5-translation focuses on improving the wellness of populations by reforming suboptimal social structures
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.
Sources: en.wikipedia.org
=== Energy manipulation === A major feature of its post-scarcity society, the Culture is obviously able to gather, manipulate, transfer and store vast amounts of energy. While not explained in detail in the novels, this involves antimatter and the "energy grid", a postulated energy field dividing the universe from neighboring anti-matter universes, and providing practically limitless energy. Transmission or storage of such energy is not explained, though these capabilities must be powerful as well, with tiny drones capable of very powerful manipulatory fields and forces. The Culture also uses various forms of energy manipulation as weapons, with "gridfire", a method of creating a dimensional rift to the energy grid, releasing astronomical amounts of energy into a region of non-hyperspace, being described as a sort of ultimate weapon more destructive than collapsed antimatter bombardment. One character in Consider Phlebas refers to gridfire as "the weaponry of the end of the universe". Gridfire resembles the zero-point energy used within many popular science fiction stories.
=== Environmentally friendly alternatives === Reusable RMW or sharps containers reduce the amount of plastic sent to landfills and CO2 emissions. Non-incineration treatment includes four basic processes: thermal, chemical, irradiative, and biological. The main purpose of the treatment technology is to decontaminate waste by destroying pathogens. Modern technology invented mechanics that would allow medical professionals and hospitals to dispose medical waste in an environmentally friendly way, such as autoclaving, plasma pyrolysis, gasification, chemical methods, and microwave irradiation. These alternatives are also highly versatile and can be used for all different types of waste. An autoclave, similar to a pressure cooker, uses high-temperature steam to penetrate waste material and kill micro-organisms. Autoclave treatment has been recommended for microbiology and biotechnology waste, waste sharps, soiled and solid wastes. Microwave irradiation is based on the principle of generation of high-frequency waves. These waves cause the particles within the waste material to vibrate, generating heat and killing the pathogens from within. A simple yet effective method is chemical disinfection: 1% hypochlorite can kill thriving bacteria. Plasma pyrolysis is an environment-friendly mechanism, which converts organic waste into commercially useful byproducts. The intense heat generated by the plasma enables it to dispose all types of waste including municipal solid waste, biomedical waste and hazardous waste in a safe and reliable manner.
== Matrix-assisted laser desorption/ionization == MALDI is an ionization technique where laser energy is absorbed by a matrix to create ions from large molecules without fragmentation. The matrix, typically in excess, is mixed with the analyte molecule and deposited on a target. A table of matrix compounds, their structures, laser wavelengths typically used, and typical application is shown below.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.